

Status: Currently Official on 14-Feb-2025  
Official Date: Official as of 01-May-2023  
Document Type: USP Monographs  
DocId: GUID-8E824CDC-1B09-4B45-94E1-0BA42459AD3F\_4\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M10498\\_04\\_01](https://doi.org/10.31003/USPNF_M10498_04_01)  
DOI Ref: yr1h8

© 2025 USPC  
Do not distribute

# Bupivacaine Hydrochloride Injection

### DEFINITION

Bupivacaine Hydrochloride Injection is a sterile solution of Bupivacaine Hydrochloride in Water for Injection. It contains NLT 93.0% and NMT 107.0% of the labeled amount of bupivacaine hydrochloride ( $C_{18}H_{28}N_2O \cdot HCl$ ).

### IDENTIFICATION

- **A.** [IDENTIFICATION—ORGANIC NITROGENOUS BASES \(181\)](#).

**Sample solution:** 2 mg/mL of bupivacaine hydrochloride in 0.01 N hydrochloric acid, from Injection

**Analysis:** Proceed as directed in the chapter beginning with “Transfer the liquid to a separator”.

**Acceptance criteria:** Meets the requirements

- **B.** The retention time of the bupivacaine peak in the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

**Change to read:**

#### • PROCEDURE

**Buffer:** 1.94 g/L of monobasic potassium phosphate and 2.48 g/L of dibasic potassium phosphate in water. Adjust, if necessary, with 1 N potassium hydroxide or 1 M phosphoric acid to a pH of 6.8.

**Mobile phase:** Acetonitrile and *Buffer* (65:35). Adjust, if necessary, with 1 M phosphoric acid to a pH of  $7.7 \pm 0.2$ . Filter the solution through a membrane filter of 1- $\mu$ m or finer pore size, and degas.

**Internal standard solution:** 1.3 mg/mL of dibutyl phthalate in methanol

**Standard solution:** 0.5 mg/mL of [USP Bupivacaine Hydrochloride RS](#), prepared as follows. In a 100-mL volumetric flask, dissolve 50 mg of [USP Bupivacaine Hydrochloride RS](#) in 10.0 mL of water, using sonication if necessary. Add 10 mL of *Internal standard solution*, and dilute with methanol to volume.

**Sample solution:** Nominally 0.5 mg/mL of bupivacaine hydrochloride, prepared as follows. In a 100-mL volumetric flask, transfer an amount of Injection equivalent to 50 mg of bupivacaine hydrochloride, add 10.0 mL of *Internal standard solution*, and dilute with methanol to volume.

#### Chromatographic system

(See [Chromatography \(621\)](#), *System Suitability*.)

**Mode:** LC

**Detector:** UV 263 nm

**Column:**  $\blacktriangle$  3.9-mm  $\blacktriangle$  (ERR 1-May-2023)  $\times$  30-cm; packing L1

**Flow rate:** 2 mL/min

**Injection volume:** 20  $\mu$ L

#### System suitability

**Sample:** *Standard solution*

[NOTE—The relative retention times for bupivacaine  $\blacktriangle$  (ERR 1-May-2023) and dibutyl phthalate are about 1.0 and 1.2, respectively.]

#### Suitability requirements

**Resolution:** NLT 2.0 between bupivacaine  $\blacktriangle$  (ERR 1-May-2023) and dibutyl phthalate

**Relative standard deviation:** NMT 1.0% for the  $\blacktriangle$  peak response  $\blacktriangle$  (ERR 1-May-2023) ratio of bupivacaine to the internal standard from three replicate injections

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of bupivacaine hydrochloride ( $C_{18}H_{28}N_2O \cdot HCl$ ) in the portion of Injection taken:

$$\text{Result} = (R_U/R_S) \times (C_S/C_U) \times 100$$

$R_U$  = peak response ratio of bupivacaine to the internal standard from the *Sample solution*

$R_S$  = peak response ratio of bupivacaine to the internal standard from the *Standard solution*

$C_S$  = concentration of [USP Bupivacaine Hydrochloride RS](#), calculated on the anhydrous basis, in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of bupivacaine hydrochloride in the *Sample solution* (mg/mL)

**Acceptance criteria:** 93.0%–107.0%

**SPECIFIC TESTS**

- **BACTERIAL ENDOTOXINS TEST** (85): NMT 2.5 USP Endotoxin Units/mg of bupivacaine hydrochloride
- **pH** (791): 4.0–6.5
- **OTHER REQUIREMENTS:** It meets the requirements in *Injections and Implanted Drug Products* (1).

**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE:** Preserve in single-dose or in multiple-dose containers, preferably of Type I glass. Injection labeled to contain 0.5% or less of bupivacaine hydrochloride may be packaged in 50-mL, multiple-dose containers.
- **USP REFERENCE STANDARDS** (11).  
[USP Bupivacaine Hydrochloride RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question                      | Contact                                       | Expert Committee          |
|-------------------------------------|---|---------------------------|
| BUPIVACAINE HYDROCHLORIDE INJECTION | <a href="#">Documentary Standards Support</a> | SM52020 Small Molecules 5 |

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 41(3)

**Current DocID:** GUID-8E824CDC-1B09-4B45-94E1-0BA42459AD3F\_4\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M10498\\_04\\_01](https://doi.org/10.31003/USPNF_M10498_04_01)

**DOI ref:** [yr1h8](#)